Galmed Pharmaceuticals Ltd.

NasdaqCM:GLMD Stock Report

Market Cap: US$4.3m

Galmed Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Galmed Pharmaceuticals has a total shareholder equity of $18.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $21.0M and $2.5M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$17.14m
EquityUS$18.44m
Total liabilitiesUS$2.51m
Total assetsUS$20.95m

Recent financial health updates

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

May 16
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 06
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

May 03
Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

Recent updates

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

May 16
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 06
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Galmed GAAP EPS of -$0.15 beats by $0.09

Aug 04

Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

May 03
Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Jan 15
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Oct 02
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?

Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

May 20
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?

Galmed gets greenlight for late-stage Aramchol NASH trial in China

May 03

What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

Feb 04
What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?

We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Dec 06
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth

Galmed EPS misses by $0.02

Nov 12

Financial Position Analysis

Short Term Liabilities: GLMD's short term assets ($17.7M) exceed its short term liabilities ($2.5M).

Long Term Liabilities: GLMD has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: GLMD is debt free.

Reducing Debt: GLMD has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GLMD has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GLMD has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 4.6% each year.


Discover healthy companies